Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
In this single arm, open label, phase 2 trial, operable patients with stage IIB-III HR+/HER2-
breast cancer will be enrolled and receive six cycles of adjuvant dalpiciclib plus letrozole.
This study aims to assessed the biological effects and safety of dalpiciclib in combination
with letrozole for HR+/HER2- breast cancer in the neoadjuvant setting.